Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | HPGDS | O60760 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29291583 | 0.83 | GPR84 (0.55) | ALPLMAPTRAB9ANPC1L3MBTL1 | |
| SCHEMBL970232 | 0.82 | ALPL (0.57) | ALPLMAPTRAB9AKMT2ANPC1 | |
| SCHEMBL1456726 | 0.81 | HPGDS (0.58) | ALPLMAPTRAB9AKMT2ANPC1 | |
| SCHEMBL1007015 | 0.81 | MAPK1 (0.61) | ALPLMAPTRAB9AKMT2ANPC1 | |
| Hydrochloric Acid SCHEMBL28348020 | 0.81 | ALPL (0.56) | ALPLMAPTRAB9AKMT2ANPC1 | |
| SCHEMBL286531 | 0.80 | MAPK1 (0.65) | ALPLMAPTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23212271 | 0.79 | ALPL (0.55) | ALPLMAPTRAB9AKMT2ANPC1 | |
| Ethane SCHEMBL6614658 | 0.79 | MAPK1 (0.59) | ALPLMAPTRAB9AKMT2ANPC1 | |
| SCHEMBL17593138 | 0.79 | ALPL (0.55) | ALPLMAPTRAB9AKMT2ANPC1 | |
| SCHEMBL16763424 | 0.79 | ALPL (0.55) | ALPLMAPTRAB9AKMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570612-B2 | Substituted nitrogen heterocyclic compound and anesthetic effect thereof | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2026-03-10 | — | — | US | disclosed |
| EP-4267574-B1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | PHARMARON UK LTD. (GB) | 2024-05-09 | — | — | US | disclosed |
| EP-4267574-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230279026-A1 | NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-20230279026-A1 | NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2023-09-07 | — | — | US | disclosed |
| US-20230099203-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20230026724-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| US-20230026724-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF | CHENGDU MFS PHARMA. CO., LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-1511751-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS INC (US) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007044410-A1 | PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007044410-A1 | PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-7196111-B2 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | SCHERING CORPORATION | 2006-05-04 | — | — | US | disclosed |
| EP-1511751-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | Neogenesis Pharmaceuticals, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | NEOGENESIS PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| WO-2003101993-A1 | PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230099203-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | ALPL 4622/4885MAPT 4844/4885RAB9A 3570/4885 |
| US-20040038993-A1 | Pyrazolo[1,5a]pyrimidine compounds as antiviral agents | RNGTT, PNP, ZC3HAV1 | ALPL 2175/4885MAPT 4292/4885RAB9A 3257/4885 |
| US-20240150345-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | ALPL 4746/4885MAPT 477/4885RAB9A 1063/4885 |
| US-20230279026-A1 | NOVEL BICYCLIC SUBSTITUTED SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY | IL1B, IL1A, IL18 | ALPL 4760/4885MAPT 2503/4885RAB9A 2925/4885 |
| US-20230026724-A1 | SUBSTITUTED NITROGEN HETEROCYCLIC COMPOUND AND ANESTHETIC EFFECT THEREOF | CYP21A2, CYP11B1, CYP11B2 | ALPL 1613/4885MAPT 2119/4885RAB9A 2046/4885 |
| US-12043632-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | ALPL 4622/4885MAPT 4844/4885RAB9A 3570/4885 |
| US-20060094706-A1 | Pyrazolopyrimidines as protein kinase inhibitors | CDKN1A, EIF2AK2, DCK | ALPL 3365/4885MAPT 3395/4885RAB9A 3288/4885 |
| US-12570612-B2 | Substituted nitrogen heterocyclic compound and anesthetic effect thereof | CNR1, SCN8A, KCNH1 | ALPL 3202/4885MAPT 3488/4885RAB9A 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.